Trials / Completed
CompletedNCT00080080
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
Phase 2 Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Point Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer (NSCLC) who have failed a prior platinum-containing regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | talabostat (PT-100) tablets | |
| DRUG | Docetaxel |
Timeline
- First posted
- 2004-03-24
- Last updated
- 2007-06-08
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00080080. Inclusion in this directory is not an endorsement.